Michael G Risbano
Overview
Explore the profile of Michael G Risbano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Zhao J, Florentin J, Tai Y, Torrino S, Ohayon L, Brzoska T, et al.
Circ Res
. 2020 Jun;
127(5):677-692.
PMID: 32493166
Rationale: Unproven theories abound regarding the long-range uptake and endocrine activity of extracellular blood-borne microRNAs into tissue. In pulmonary hypertension (PH), microRNA-210 (miR-210) in pulmonary endothelial cells promotes disease, but...
13.
Zou R, Wallace W, Nouraie S, Chan S, Risbano M
Pulm Circ
. 2020 Mar;
10(1):2045894019891912.
PMID: 32128158
Exercise pulmonary hypertension is an underappreciated form of physical limitation related to early pulmonary vascular disease. A low diffusing capacity of lungs for carbon monoxide (DLco) can be seen in...
14.
Pi H, Kosanovich C, Handen A, Tao M, Visina J, VanSpeybroeck G, et al.
Chest
. 2020 Feb;
158(1):330-340.
PMID: 32109446
Background: Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary arterial pressures and is managed by vasodilator therapies. Current guidelines encourage PAH management in specialty care centers (SCCs), but evidence...
15.
Hansmann G, Calvier L, Risbano M, Chan S
Am J Respir Cell Mol Biol
. 2019 Oct;
62(2):143-156.
PMID: 31577451
Translational research is essential to the development of reverse-remodeling strategies for the treatment of pulmonary vascular disease, pulmonary hypertension, and heart failure via mechanistic studies using animal models resembling human...
16.
Rivera-Lebron B, Cruz Morel K, Risbano M
Respirology
. 2019 Aug;
25(4):354-355.
PMID: 31454132
No abstract available.
17.
DAlessandro A, Reisz J, Zhang Y, Gehrke S, Alexander K, Kanias T, et al.
Blood Adv
. 2019 Mar;
3(6):884-896.
PMID: 30890545
Cold storage of blood for 5 to 6 weeks has been shown to impair endothelial function after transfusion and has been associated with measures of end-organ dysfunction. Although the products...
18.
Estephan L, Genuardi M, Kosanovich C, Risbano M, Zhang Y, Petro N, et al.
Pulm Circ
. 2019 Mar;
9(2):2045894019840646.
PMID: 30854934
Pulmonary hypertension (PH), a heterogeneous vascular disease, consists of subtypes with overlapping clinical phenotypes. MicroRNAs, small non-coding RNAs that negatively regulate gene expression, have emerged as regulators of PH pathogenesis....
19.
Wallace W, Nouraie M, Chan S, Risbano M
Pulm Circ
. 2018 Jun;
8(3):2045894018787381.
PMID: 29916285
Exercise pulmonary hypertension (ePH) is an underappreciated form of exertional limitation. Despite normal resting pulmonary artery pressures, patients with ePH demonstrate early pulmonary vascular changes with reduced pulmonary arterial compliance...
20.
Coons J, Bunner C, Ishizawar D, Risbano M, Rivera-Lebron B, Mathier M, et al.
Pulm Circ
. 2017 Dec;
8(1):2045893217744512.
PMID: 29199910
Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however,...